MVI DNA vaccines are poised to differentiate PD-1 inhibitors and standard-of-care AR axis inhibitors across the disease spectrum of prostate cancer
MVI has two DNA plasmid vaccines specifically targeting prostate cancer that are currently in Pilot Phase II development trials across the major stages of disease progression. We have excellent safety, and clinical efficacy signals in combination with PD-1 inhibitors and AR axis antagonists.
MVI recognizes that not all partners want the same relationships. MVI is open to development strategies that could include MVI's continued development responsibilities under standard option structures, asset transfers, or joint development initiatives.
MVI has moved both of its assets well beyond preclinical animal models. Human safety and tolerability risks are retired. Manufacturing processes are robust with 5 lots of cGMP clinical material produced without a failure.
We have significant data on preferred dosing schedules for combination therapies.